Online inquiry

IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8670MR)

This product GTTS-WQ8670MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM), AL amyloidosis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ8670MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13092MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ13586MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ3921MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ12422MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ5541MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ3594MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ10885MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ10515MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY3002813
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW